| Today's Edition
Thursday May 5th, 2016
Stay ahead of the pack with "The QualityStocks Daily", our summary formatted newsletter
containing stock tips from hundreds of online investment newsletters.
Daily.QualityStocks.net
OWC Pharmaceutical Research Corp. (OWCP)
CFN Media Group and Cannabis Financial Network News reported recently on OWC Pharmaceutical Research Corp. (OWCP), and we report today on the Company, here at the QualityStocks Daily Newsletter.
OWC Pharmaceutical Research Corp. engages in the research and development of Cannabis-based medical products. It provides medical products for the treatment of different medical conditions and/or diseases. This includes multiple myeloma, psoriasis, PTSD, and migraines; as well as delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. The Company is headquartered in Petach Tikva, Israel.
One World Cannabis’ Research Division concentrates on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of diverse medical conditions. Its Consulting Division’s dedication is to helping governments and companies navigate complex international cannabis regulatory frameworks.
Essentially a medical cannabis research and development company, OWC Pharmaceutical Research has entered into research and collaboration agreements with three of the leading research institutions in Israel. This includes Sheba Academic Medical Center, one of the foremost academic hospitals in the Middle East. These agreements serve as the framework for OWC’s clinical trials, and ensure that all of the Company’s studies have been, and will continue to be, based on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.
OWC Pharmaceutical Research announced in June of last year that its wholly-owned subsidiary, One World Cannabis, announced it received the first basic science study (lab) results on the effect of several combinations of Cannabidiol (CBD) and tetrahydrocannabinol (THC) on multiple myeloma cell line RPMI8226.
Based on the results, One World Cannabis submitted the clinical trial protocol to the IRB (Helsinki committee). The OWC multiple myeloma study was done by three repetitive tests on the effect of cannabis extract with different combination ratios of THC/CBD and pure THC and CBD (50 percent concentration). The results present greater than 60 percent malignant cell death.
Recently, OWC Pharmaceutical Research announced that it completed in-vitro testing on its formulation for multiple myeloma. The Company is preparing to start pre-clinical safety and efficacy studies on mice. Its in-vitro testing indicated that specific formulations of CBD and THC decreased survival of multiple myeloma cells in a concentration-dependent manner, and resulted in 100 percent malignant cell death in 60 percent of cases. This formulation will now undergo testing in a pre-clinical, IRB approved protocol on mice in an effort to duplicate the results.
OWC Pharmaceutical Research Corp. (OWCP), closed Thursday's trading session at $0.07, up 16.67%, on 3,950 volume with 3 trades. The average volume for the last 60 days is 41,182 and the stock's 52-week low/high is $0.01/$0.30
|
